AbbVie
ABBV
#26
Rank
NZ$691.65 B
Marketcap
NZ$391.34
Share price
-1.15%
Change (1 day)
33.27%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2025 (TTM): NZ$2.32

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$2.34. In 2024 the company made an earnings per share (EPS) of NZ$4.19 a decrease over its 2023 EPS that were of NZ$4.76.

EPS history for AbbVie from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$2.32-44.78%
2024NZ$4.19-11.86%
2023NZ$4.76-58.95%
2022NZ$11.592.49%
2021NZ$11.31121.58%
2020NZ$5.10-44.7%
2019NZ$9.2345.84%
2018NZ$6.339.72%
2017NZ$5.77-9.54%
2016NZ$6.3716.28%
2015NZ$5.48184.1%
2014NZ$1.93-57.15%
2013NZ$4.50

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.98 27.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$5.14 119.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$35.52 1,417.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$22.55 863.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$11.29 382.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$19.02 712.95%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$6.22 166.00%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$5.25 124.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$7.46 218.82%๐Ÿ‡บ๐Ÿ‡ธ USA